Blood test monitoring after colon cancer surgery
Part of Cancer, Digestive system clinical trials.
This study watches for signs of leftover cancer after surgery using a blood test (MRD). It is for people with early-stage colon cancer who have not yet had any treatment other than surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have colon adenocarcinoma (a type of colon cancer) that has not spread beyond the colon wall (stages I, II, or III)
- You have not had chemotherapy, radiation, or other cancer treatments for this cancer yet
- You can have surgery to remove the entire tumor
- You are in good overall health (ECOG score 0 or 1) and can cooperate with follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test (MRD) to monitor for cancer return after surgery in patients with stage IV colorectal cancer that can be removed. The goal is to catch any recurrence early and guide further treatment.
This trial tests whether a special blood test (MRD) can help monitor your rectal cancer after surgery, to catch any signs of remaining cancer early. It's for people with advanced but not metastatic rectal cancer that can be removed with surgery, and who haven't started any cancer treatment yet.
This study helps doctors decide whether you need chemotherapy after colon cancer surgery by checking for cancer DNA in your blood. The goal is to give chemotherapy only to patients who truly need it, based on what the blood test shows.
This study looks at a blood “DNA” test to see if it can help monitor colorectal cancer after surgery. It may benefit you by improving how doctors track cancer during routine follow-up visits.
This study tests if a simple blood test can detect early signs of colorectal cancer coming back after surgery to remove cancer spread in the abdomen. It may help patients avoid unnecessary treatments and catch recurrence sooner.
This study measures “minimal residual disease,” meaning tiny amounts of cancer that may remain after surgery, using blood samples. It may help doctors better detect who is at higher risk of cancer coming back and guide follow-up care.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.